Literature DB >> 14623361

The genetics of schizophrenia: glutamate not dopamine?

David A Collier1, Tao Li.   

Abstract

The major targets of current drugs used in mental health, such as neurotransmitter receptors and transporters, are based on serendipitous findings from several decades ago, and there is currently a severe drought of new drug targets. There is a pressing need for novel drugs, and much hope has been placed on the use of molecular genetics to help define them. However, despite evidence for a genetic basis to schizophrenia stretching back for over a century, and a heritability of about 80%, the identification of susceptibility genes has been an uphill struggle. Candidate gene studies, which have generally focussed on obvious candidates from the dopamine and serotonin systems, as well as genes involved in brain development, have not generally been successful, although meta-analysis indicates that the dopamine D3 receptor gene (DRD3) and the serotonin receptor gene type 2A (HTR2A) may have a very small influence on risk. Linkage analysis has provided robust evidence of genetic loci, for example, on chromosomes 8p, 13q and 22q, and also implies shared genetic aetiology with bipolar disorder. The identification of these loci together with advances in genetic technology, especially the characterisation of polymorphisms, the understanding of haplotypes and the development of statistical methods, has lead to the identification of several plausible susceptibility genes, including neuregulin 1, proline dehydrogenase and dysbindin. Interestingly, these genes point more towards a role for the glutamate pathway rather than the dopamine pathway in schizophrenia. We have attempted to replicate some of these findings in schizophrenic patients from SW China, and we find significant association with a novel neuregulin 1 haplotype, with proline dehydrogenase polymorphisms, but not with catechol-O-methyltransferase (COMT). The replication of neuregulin 1 association on chromosome 8p by several investigators is the most convincing to date, and the presence of a syndrome similar to dementia praecox of 8p linked families, and the lack of linkage of bipolar disorder to this region is a testament to the ideas of Kraepelin more than 100 years ago.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623361     DOI: 10.1016/j.ejphar.2003.08.105

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

Review 1.  Schizophrenia: an update and review.

Authors:  Jehannine Austin
Journal:  J Genet Couns       Date:  2005-10       Impact factor: 2.537

Review 2.  Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes?

Authors:  Wolfgang Maier; Barbara Höfgen; Astrid Zobel; Marcella Rietschel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 3.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

4.  Molecular and cellular characterization of Neuregulin-1 type IV isoforms.

Authors:  Alon Shamir; Andres Buonanno
Journal:  J Neurochem       Date:  2010-03-10       Impact factor: 5.372

Review 5.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

6.  Lack of associations of neuregulin 1 variations with schizophrenia and smooth pursuit eye movement abnormality in a Korean population.

Authors:  Jeong-Hyun Kim; Byung-Lae Park; Charisse Flerida A Pasaje; Joon Seol Bae; Chul Soo Park; Boseok Cha; Bong-Jo Kim; Migyung Lee; Woo Hyuk Choi; Tae-Min Shin; Ihn-Geun Choi; Jaeuk Hwang; Insong Koh; Sung-Il Woo; Hyoung Doo Shin
Journal:  J Mol Neurosci       Date:  2011-08-20       Impact factor: 3.444

7.  The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis.

Authors:  Dion K Dickman; Graeme W Davis
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

8.  Exploring genetic counselors' perceptions of and attitudes towards schizophrenia.

Authors:  Laura C Monaco; Laura Conway; Kathleen Valverde; Jehannine C Austin
Journal:  Public Health Genomics       Date:  2009-03-26       Impact factor: 2.000

Review 9.  Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

Authors:  Maju Mathew Koola; Robert W Buchanan; Anilkumar Pillai; Katherine J Aitchison; Daniel R Weinberger; Scott T Aaronson; Faith B Dickerson
Journal:  Schizophr Res       Date:  2014-05-28       Impact factor: 4.939

10.  Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia.

Authors:  Kazuo Yamada; David J Gerber; Yoshimi Iwayama; Tetsuo Ohnishi; Hisako Ohba; Tomoko Toyota; Jun Aruga; Yoshio Minabe; Susumu Tonegawa; Takeo Yoshikawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.